Concerns over record-high inflation, the Federal Reserve’s persistent hawkish stance, geopolitical tensions, and a potential recession have fostered heightened market volatility this year.
Despite various macro headwinds, diversified healthcare company Johnson & Johnson (JNJ) managed to beat top and bottom-line estimates for the third quarter of fiscal 2022. The company’s adjusted operational sales grew 8.2% year-over-year, while its net earnings increased 21.6% year-over-year.
